Week 14/2020 (30 March – 5 April 2020)
- The novel coronavirus disease 2019 (COVID-19) outbreak in the Region is affecting healthcare presentations and testing capacities in Member States, which impact both influenza epidemiological and virological data, and seasonal patterns; therefore the data we present must be interpreted with caution.
- For the Region overall, influenza activity appears to be declining: high or medium influenza intensity were reported by 2 Member States, and none reported widespread influenza activity.
- The percentage of specimens from patients who presented with ILI or ARI to sentinel primary healthcare sites that tested positive for an influenza virus, was 4% in week 14/2020.
- Both influenza virus types A and B were co-circulating in sentinel source specimens: of 17 viruses detected, 7 were influenza type A and 10 were influenza type B.
- Pooled estimates of all-cause mortality show a marked increase in excess mortality overall within participating countries, related to the COVID-19 pandemic. This excess mortality is driven by a very substantial excess mortality in some countries, primarily seen in the age group 65 years and older, but also in the age group 15-64 years.
2019/20 season overview
- For the Region as a whole, influenza activity commenced earlier than in recent years and, based on sentinel sampling, first exceeded a positivity rate of 10% in week 47/2019.
- The influenza season for the Region as a whole peaked in week 05/2020, reaching a maximum positivity rate of 55%. The peak phase with positivity levels above 50% lasted for just two weeks, 05/2020 and 06/2020, but reporting in subsequent weeks may have been adversely affected by Member State responses to the COVID-19 outbreak. In the previous influenza season, the influenza positivity rate exceeded 50% for six weeks.
- The majority of circulating viruses were susceptible to neuraminidase inhibitors supporting early treatment or prophylactic use according to national guidelines.
- Interim estimates of 2019–2020 seasonal influenza vaccine effectiveness in the northern hemisphere are available. Vaccination remains the best possible method for prevention of influenza and/or reducing the risk of serious complications.
- WHO has published recommendations for the composition of influenza vaccines to be used in the 2020–2021 northern hemisphere season. Based on these recommendations, the influenza A(H1N1)pdm09, A(H3N2) and B/Victoria-lineage virus components should be updated for the 2020–2021 influenza vaccine.
- ECDC and WHO Regional Office for Europe published a joint Regional Situation Assessment for the 2019–2020 influenza season up to week 49/2019, which focused on disease severity and the impact on healthcare systems, to assist forward planning in Member States.
The World Health Organization categorized the COVID-19 outbreak as a pandemic on 11 March 2020. The number of COVID-19 cases being reported within the European Region has continued to increase significantly. For more information visit: